Cargando…

Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging

PURPOSE: Current clinical imaging of PSMA-positive prostate cancer by positron emission tomography (PET) mainly features (68)Ga-labeled tracers, notably [(68)Ga]Ga-PSMA-HBED-CC. The longer half-life of fluorine-18 offers significant advantages over Ga-68, clinically and logistically. We aimed to dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, James, Amor-Coarasa, Alejandro, Nikolopoulou, Anastasia, Kim, Dohyun, Williams, Clarence, Ponnala, Shashikanth, Babich, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323493/ https://www.ncbi.nlm.nih.gov/pubmed/27847991 http://dx.doi.org/10.1007/s00259-016-3556-5

Ejemplares similares

(66)Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?
por: Amor-Coarasa, Alejandro, et al.
Publicado: (2018)

[(18)F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4
por: Amor-Coarasa, Alejandro, et al.
Publicado: (2019)

Otto: a 4.04 GBq (109 mCi) (68)Ge/(68)Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [(68)Ga]Ga-PSMA-11
por: Waterhouse, Nicole N., et al.
Publicado: (2020)

Synthesis and Evaluation of (11)C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography
por: Kelly, James M., et al.
Publicado: (2022)

A general (11)C-labeling approach enabled by fluoride-mediated desilylation of organosilanes
por: Qu, Wenchao, et al.
Publicado: (2020)

3D-printed automation for optimized PET radiochemistry
por: Amor-Coarasa, Alejandro, et al.
Publicado: (2019)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

[(18)F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response
por: Zhang, Hanwen, et al.
Publicado: (2022)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
por: Kelly, James M., et al.
Publicado: (2021)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Value of (18)F-PSMA-PET/MRI for Assessment of Recurring Ranula
por: Tilsen, Felix, et al.
Publicado: (2021)

A novel (18)F-labelled high affinity agent for PET imaging of the translocator protein
por: Blair, Adele, et al.
Publicado: (2015)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain
por: Syvänen, Stina, et al.
Publicado: (2020)

A High-Affinity (64)Cu-Labeled Ligand for PET Imaging of Hepsin: Design, Synthesis, and Characterization
por: Park, Ji-Hun, et al.
Publicado: (2022)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Single-Center Comparison of [(64)Cu]-DOTAGA-PSMA and [(18)F]-PSMA PET–CT for Imaging Prostate Cancer
por: Mirzaei, Siroos, et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
por: Varasteh, Zohreh, et al.
Publicado: (2013)

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake
por: Basuli, Falguni, et al.
Publicado: (2022)

Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
por: Zhou, Haoxi, et al.
Publicado: (2021)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

(68)Ga-PSMA PET/CT Versus (18)F-FDG PET/CT for Imaging of Hepatocellular Carcinoma
por: Gündoğan, Cihan, et al.
Publicado: (2021)

(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
por: Grubmüller, B., et al.
Publicado: (2017)

Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
por: Treglia, Giorgio, et al.
Publicado: (2019)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Preclinical evaluation and first in human study of Al(18)F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rv9nt8j0m0o35qibuv4qerj3v2